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Background: Atherosclerosis, the underlying cause of heart attack and strokes, is a progresive dyslipidemic and
inflammatory disease where monocyte-derived macrophage cells play a pivotal role. Although most of the mechanisms
that contribute to the progression of atherosclerosis have been identified, there is limited information on those
governing regression. Conjugated linoleic acid (CLA) is a group of isomers of linoleic acid that differ in the position and/or
geometry of their double bonds. We have previously shown that a specific CLA blend (80:20 cis-9,trans-11:trans-10,cis-12-
CLA) induces regression of pre-established atherosclerosis in vivo, via modulation of monocyte/macrophage function.
However, the exact mechanisms through which CLA mediates this effect remain to be elucidated.
Methods: Here, we address if CLA primes monocytes towards an anti-inflammatory MΦ2 macrophage and examine the
effect of individual CLA isomers and the atheroprotective blend on monocyte-macrophage differentiation, cytokine
generation, foam cell formation and cholesterol metabolism in human peripheral blood monocyte (HPBMC)-derived
macrophages.
Results: cis-9,trans-11-CLA and the atheroprotective 80:20 CLA blend regulates expression of pro-inflammatory mediators
and modulates the inflammatory cytokine profile of macrophages and foam cells. In addition, cis-9,trans-11-CLA and CLA
blend primes HPBMCs towards an anti-inflammatory MΦ2 phenotype, characterised by increased scavenger receptor
(CD36) and efflux protein (ABCA-1) expression. Furthermore, this altered macrophage phenotype impacts on foam cell
formation, inhibiting ox-LDL accumulation and promoting cholesterol efflux via both PPARγ and LXRα
dependent pathways.
Conclusion: The data increases the understanding of the pathways regulated by CLA in atheroprotection, namely,
inhibiting the progressive acquisition of a pro-inflammatory macrophage phenotype.
Keywords: Conjugated linoleic acid, Atherosclerosis, Macrophage differentiation, Foam cell formation, Scavenger
receptors, Cholesterol effluxBackground
Biologically active macrophage cells play a pivotal role in
atherosclerosis development from the early stages of
monocyte to macrophage differentiation, intimal accu-
mulation of macrophages and their conversion to foam
cells via uptake of oxidised lipid, to the later stage of fi-
brous plaque development. In the context of atheroscler-
osis, the underlying cause of myocardial infarction and* Correspondence: orina.belton@ucd.ie
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ity regulating and sustaining the chronic inflammatory
response and regulating lipid accumulation and metabol-
ism [1], two of the most well documented pathways as-
sociated with the pathogenesis of the disease.
At sites of atherosclerotic lesion development, LDL
passively diffuses through the tight junction of the dys-
functional endothelium [2], where it becomes oxidised
as a result of exposure to the oxidative stress of vascular
cells thus giving rise to minimally oxidised-LDL which
stimulates the overlying endothelial cells to express pro-
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wall [3]. Monocytes adhere to the activated endothelial
cells via specific interactions mediated by integrins [4] and
following transendothelial migration, rapidly differentiate
into macrophages in response to growth factors, such as
macrophage colony-stimulating factor (M-CSF). M-CSF is
required for the survival of both circulating monocytes
and resident tissue macrophages [5] and potentiates a
number of monocyte functions including phagocytic activ-
ity, microbial killing, tumor cell cytotoxicity, enhanced
synthesis of inflammatory cytokines [6], and, of relevance
to this study, differentiation of the monocyte cell into a
mature macrophage. In atherosclerosis M-CSF mediates
other macrophage-specific programmes, such as scavenger
receptor (SR) and apo-E gene expression [7].
ox-LDL is taken up by the mature macrophage via scav-
enger receptor-mediated endocytosis, primarily CD36 and
SR-A1, through endosomes. Endosomes-containing ox-
LDL are trafficked to lysosomes where the cholesterol
ester content of the ox-LDL is hydrolysed to fatty acids
and free cholesterol, which is then trafficked out of the
lysosome where it is re-esterified to cholesterol esters by
acyl-coenzyme A:cholesterol acetyltransferase (ACAT).
Cholesterol esters are stored in the cytosol or cleaved by
the neutral cholesterol ester hydrolase to free cholesterol
which is then effluxed from the macrophage via several
transporters, including ATP-binding cassette (ABC) family
(ABCA-1, ABCG-1) and SR-B1 to acceptor molecules,
such as apo-A1 and HDL for subsequent metabolism in
the liver [8,9]. This reverse cholesterol transport (RCT)
pathway is regulated by the nuclear receptor Liver X Re-
ceptor (LXR).
During early stages of atherosclerosis, the concentra-
tions of ox-LDL in the intima are sufficiently low for
macrophage-mediated removal. However, as disease
progresses and concentrations of ox-LDL increase, the
balance between efflux and influx is altered, the RCT
system is overwhelmed and free cholesterol is stored as
cholesterol esters in the form of cytosolic lipid droplets.
The accumulation of lipid droplets in the macrophage is
indicative of foam cell formation and results in the fatty
streak, the first clinical hallmark of atherosclerotic
plaque [10].
Macrophages are heterogeneous cell populations, of
which the pan macrophage marker is CD68, a glycopro-
tein present on the lysosomal membrane of the cell that
adapts a response to environmental cytokines. Macro-
phages respond to stimuli from their micro-environment
and, consequently, show high plasticity and heterogeneity
[11]. The initial simplified classification of macrophage
phenotypes is the discrimination between type-1 pro-
inflammatory (MΦ1) and type-2 anti-inflammatory (MΦ2)
macrophages on the basis of the cytokine environment cre-
ated by two different classes of lymphocyte T helper (TH1or TH2). Classically activated MΦ1 pro-atherogenic macro-
phages are primed by TH1 cytokines, such as IFN-γ and
IL-1β, and function to increase and sustain the ongoing in-
flammatory response via production of pro-inflammatory
mediators, such as TNF-α, IL-6, IL-1β and IL-12. Thus,
continuous MΦ1 macrophage activity, contributes to tissue
damage [1,12]. Alternatively activated MΦ2 anti-
inflammatory macrophages are primed as a result of expos-
ure to TH2 cytokines, such as IL-4 and IL-13 [13] and
promote tissue repair and healing. Both MΦ1 and MΦ2
macrophages have been identified in human atheroscler-
otic plaque where MΦ2 macrophages are present at more
stable locations [14]. More recently, it has been shown that
the MΦ1 macrophage content of atherosclerotic plaques is
associated with clinical incidence of ischemic stroke and
increased inflammation [15]. Furthermore, it has been
shown that there is an MΦ2 to MΦ1 switch during athero-
sclerotic plaque progression, suggesting that interventional
tools which could revert the macrophage infiltrate towards
the MΦ2 phenotype, may exert an atheroprotective action
[16]. We have previously shown that, in a conjugated lino-
leic acid (CLA)-induced model of atherosclerosis regres-
sion, there is enrichment of MΦ2 genes in the aorta in vivo
[17] which is in agreement with other studies which show
that decreased lipid levels are associated with lower plaque
lipid content and higher MΦ2 gene expression [18].
CLA is a family of naturally occurring geometric die-
noic isomers of the ω6 essential fatty acid, linoleic acid
(LA) [19]. CLA has a diverse range of benefits in health
and diseases such as cancer [20,21], obesity [22,23], im-
mune function [24] and atherosclerosis [25-28].
We have previously shown that dietary administration
of a 1% CLA blend of the two most abundant isomers
(80:20, cis-9,trans-11-CLA:trans-10,cis-12-CLA) in-
duces regression of pre-established atherosclerosis in
the apo-E−/− mouse model, despite a continuing high
cholesterol challenge [25], via modulation of monocyte/
macrophage function [29,30].
Moreover, we have shown that CLA inhibits foam cell
formation in vitro, via regulation of the nuclear receptor
coactivator, peroxisome proliferator-activated receptor
(PPAR)-γ coactivator (PGC)-1α [31]. Of relevance to this
study, we have also shown that CLA increased macro-
phage polarization toward an anti-inflammatory MΦ2
phenotype in vivo [17] and that this is mediated via
PPARγ dependent and independent mechanisms.
The effects of CLA on cholesterol homeostasis and foam
cell formation have also been investigated in macrophage
cell lines where t-10,c-12-CLA and c-9,t-11-CLA decreased
foam cell formation [32] and increased expression of genes
involved in RCT, such as LXRα and its target gene ABCA-
1. In addition, levels of pro-inflammatory cytokine produc-
tion (in particular TNF-α, IL-6 and IL-1β) were decreased
following treatment with four different CLA isomers (cis-9,
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CLA) in RAW-264.7 macrophages via a PPARγ dependent
mechanism [33]. However, to date, studies with CLA on
primary HPBMCs are limited.
The aim of this study is to investigate the effects of the
atheroprotective CLA isomer c-9,t-11-CLA, the athero-
protective CLA blend (80:20 c-9,t-11:t-10,c-12-CLA) and
the t-10,c-12-CLA isomer on the monocyte-macrophage-
foam cell axis, specifically to identify changes in macro-
phage phenotype, inflammatory cytokine generation and
cholesterol uptake and transport using HBPMC-derived
macrophages, to ultimately further understand the mecha-
nisms through which CLA mediates regression of pre-
established atheroslerosis. Here, we provide evidence that
CLA shifts HPBMC-derived macrophage differentiation to
an anti-inflammatory phenotype, inducing expression of
MΦ2 marker receptors and suppressing production of
pro-inflammatory cytokines. Additionally, we show that
CLA inhibits foam cell formation by reducing ox-LDL up-
take and increasing cholesterol efflux. Our data describes
a novel functional role for CLA in regulating macrophage
phenotype and foam cell formation in the context of ath-
erosclerosis regression.
Methods
Isolation of human peripheral blood monocytes
All experiments were conducted in conformity with in-
stitutional guidelines and in compliance with inter-
national laws. All volunteers gave written informed
consent. Whole blood from healthy volunteers was
drawn into heparin-coated vacutainers (BD, UK/Ireland).
All volunteers were non-smoking, aged 25–30 years and
free from medication for at least 10 days. Platelet-rich
plasma (PRP) was isolated by centrifugation (190 × g for
15 min) and then diluted 1:3 with PBS before addition
to Lymphoprep (Nycomed, Norway) and centrifuged at
450 × g for 30 min. Buffy-coats were recovered using a
pasteur pipette, washed twice with PBS and resuspended
in 10 ml serum-free medium (SFM) M-199 (Thermo Sci-
entific), supplemented with L-glutamine (6.8 mM) and an-
tibiotics (100 U/mL penicillin, 100 μg/mL streptomycin)
and 10 ng/ml polymyxin-B-sulfate (Sigma-Aldrich, Dublin,
Ireland). Monocytes were purified by plastic adherence in
SFM for 2 hrs at 37°C, 5%CO2.
HPBMC-derived macrophage differentiation and cell
treatment
Prior to in vitro experiments, macrophage differentiation of
freshly isolated HBPMCs was stimulated with 100 ng/ml
M-CSF (Gibco-BRL Life Technologies Ltd, England, UK),
in 10% human serum (HS) (Sigma-Aldrich, Dublin,
Ireland). After four days of culture at 37°C, 5%CO2, media
was changed and a further 100 ng/ml M-CSF was added in
10% HS (Additional file 1).For experiments on differentiating macrophages, cells
were washed twice with warm PBS and treated for 48
hrs at 37°C, 5%CO2, in 1% HS, with 10 μM of cis-9,
trans-11-CLA, trans-10,cis-12-CLA , CLA blend (80:20
c-9,t-11:t-10,c-12); linoleic acid (LA) and oleic acid (OA)
(all Cayman Chemicals, MI, USA); 5 μM PPARγ agonist,
troglitazone (TROG) or dimethyl sulfoxide (DMSO) (ve-
hicle control) (both Sigma-Aldrich, Dublin, Ireland) at
day 4 of culture. At day 6 cells were fixed for immuno-
cytochemistry or lysed for mRNA analysis.
For experiments on mature macrophages and foam
cell formation, media was changed and further 100 ng/
ml M-CSF were added in 10% HS after four days of cul-
ture at 37°C, 5%CO2. Cells were treated with CLA and
controls as above at day 8 and fixed at day 10. Where
relevant, cells were also treated with 1 μM LXRα agon-
ist T0901317 (T1317) or 10 μM 25-hydroxycholesterol
(25-OH) (both from Sigma-Aldrich, Dublin, Ireland).HPBMC-derived foam cell formation
After ten days of culture, as above described, mature
macrophage were washed twice with warm PBS and in-
cubated for further 4 hrs with 50 μg/ml of human ox-
LDL or human fluorescently labelled Dil-ox-LDL (both
Intracel MD, USA).
Following CLA and control treatments lipid loading,
wells were washed three times with fresh medium and
fluorescent Dil emission was measured in a Spectramax
M2 (Molecular devices, CA, USA) plate fluorescence
reader with 550/568 nm excitation/emission wavelength.
The levels of Dil-ox-LDL were adjusted per cell number
by measuring the intensity of DAPI fluorescence, with a
second reading at 360/460 nm. Ox-LDL uptake mea-
surements were repeated in triplicate in three independ-
ent experiments and the mean value was expressed as a
percentage of vehicle control.THP-1 cell culture and cell treatments
Human THP-1 monocytes (ATCC) were cultured in
RPMI 1640 medium supplemented with fetal bovine
serum (10%), penicillin (100 U/ml), streptomycin (100
ug/ml) and L-glutamine (2 mM) (Gibco BRL, UK).
THP-1 monocytes (1 × 106) were differentiated to mac-
rophages using 100 nmol/L phorbol 12-myristate 13-
acetate (PMA) (Sigma Aldrich, Dublin, Ireland) for
72 hrs.
THP-1 macrophage were treated for 18 hrs with DMSO,
25 μM of c-9,t-11-CLA and CLA blend, TROG (10 μM),
T1317 (1 uM), alone or pre-incubated for 2 hrs with
10 μM of the PPARγ inhibitor, GW9662 (GW) (Cayman
Chemicals, MI, USA), or 1 μM of the LXRα inhibitor,
GSK2033, (GSK) (Axon).
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For gene expression experiments, HBPMC- or THP-1-
derived macrophages and HPBMC-derived foam cells
were washed twice with ice cold PBS, prior to addition
of 200 μl of RLT buffer (Qiagen, UK). Total RNA was
isolated from cell lysates using the RNeasy kit (Qiagen,
UK) as per manufacturers’ instructions. Reverse tran-
scription was carried out on 1 μg of total RNA using
SuperscriptTM III Reverse Transcriptase (Invitrogen) ac-
cording to the manufacturers’ instructions. Relative gene
expression quantification by real-time PCR (RT-PCR)
was performed on an ABI Prism 7900HT Sequence
Detection System (Applied Biosystems Inc., UK). MR and
SRA-1 expression were examined using specific Taqman
assays (Applied Biosystems Inc., UK), whilst, ABCA-1,
CD36, CD14, CD68 and CD163 were measured using spe-
cific Syber green assays (Applied Biosystems Inc., UK)
(Additional file 2). Ct values were normalised to 18s ribo-
somal RNA.
Immunocytochemistry
For visualisation of HPBMC-derived macrophages and
foam cells, 5x105 cells were seeded onto glass coverslips
placed in 12-well plate and treated, as above, over 6 days
of culture. Mature macrophages or ox-LDL loaded-foam
cells were then fixed in 3% formaldehyde (Sigma-Aldrich,
Dublin, Ireland), permeabilized with Triton-X-100 (Sigma-
Aldrich, Dublin, Ireland). Non-specific binding was pre-
vented by blocking with 5% BSA (Sigma-Aldrich, Dublin,
Ireland). Target proteins were then labelled using 1:100 of
anti-human goat polyclonal CD68 and goat polyclonal MR
(Sigma-Aldrich) and fluorescently labelled-secondary anti-
bodies (1:200 of Alexa-Fluor 488, 568 or 647) (Invitrogen,
Carlsbad, California), followed by Alexa Fluor 568-
phalloidin staining (Invitrogen, Carlsbad, California), for
F-actin, and DAPI (Sigma-Aldrich, Dublin, Ireland). For
foam cell visualization, only DAPI staining was required as
fluorescently labelled ox-LDL was used (Dil emission at
568nm). Cells were imaged using a Zeiss AxioImager M1
fluorescent microscope and the images were captured
using an Olympus digital camera (Optronics, Goleta, CA).
Intracellular cholesterol measurement
Intracellular cholesterol levels were measured using the
Amplex® Red Cholesterol Assay kit (Molecular Probes),
based on an enzyme-coupled reaction that detects both
free and esterified cholesterol.
After 10 days of culture and treatment with CLA iso-
mers and controls as described above, HPBMC-derived
macrophages and foam cells were lysed using T-PER.
Firstly, a cholesterol standard curve was prepared, dilut-
ing the cholesterol reference standard. The Amplex Red
reagent, containing the substrate HRP and both choles-
terol oxidase/esterase, enzymes was prepared accordingto the manufacturers’ guidelines. 50 μl Amplex Red re-
agent was added to each sample and the samples were
then incubated for 30 mins at 37°C. Fluorescence was
measured using a microplate reader, using excitation in
the range of 530–560 nm and emission detection
at ~590 nm. Each point was corrected for background
fluorescence by subtracting the values derived from the
no-cholesterol control.
ELISA for cytokine quantification
Following 10 days of differentiation firstly to macro-
phages, and subsequenty to foam cells following expos-
ure to ox-LDL, in the presence of CLA isomers or
appropriate controls, as described above, HBPMC-
derived macrophage/foam cell supernatants were col-
lected and cleared by centrifugation (10,000 × g for 10
min at 4°C). The concentration of IL-10, IL-6, IL-1β,
INF-γ, TNF-α and IL12-p70 in conditioned media was
determined by enzyme immunoassay (EIA) using com-
mercially available human 96 well-plate multiplex kit for
tissue culture samples (MSD, Gaithersburg, MD, USA)
according to the manufacturers’ guidelines.
Statistical analysis
Results are expressed as mean ± SEM or fold change rela-
tive to vehicle control. Experimental points were performed
in triplicate with a minimum of three independent experi-
ments (n = 3). Statistical comparisons between controls ver-
sus treated groups were made by Student’s unpaired t-test,
assuming unequal variance with a two-tailed distribution. A
value of p < 0.05 or greater were considered significant.
Results
CLA primes human monocytes towards an MΦ2
phenotype
To elucidate if the atheroprotective CLA blend (80:20 c-
9,t-11:t-10,c-12-CLA) impacts on monocyte-macrophage
differentiation, we analysed the mRNA expression of the
pan-monocyte and pan-macrophage markers, CD14
and CD68, respectively (Figure 1a), and of the MΦ2-
type macrophage markers mannose receptor (MR)
and CD163 (Figure 1b) in unstimulated or M-CSF-
stimulated HPBMCs. Unstimulated monocyte cells
were maintained in culture for 6 days, as a model of
early macrophage differentiation, and M-CSF treated
HPBMCs were used as a model of mature differenti-
ated macrophages. Following 6 days of culture, un-
stimulated and M-CSF-stimulated macrophages were
treated with 10 μM cis-9,trans-11-CLA (c-9,t-11-CLA),
trans-10,cis-12-CLA (t-10,c-12-CLA), CLA blend
(80:20 c-9,t-11:t-10,c-12), linoleic acid (LA), oleic acid
or 5 μM of the PPARγ agonist, troglitazone (TROG)
and analysed for expression of macrophage markers by
RT-PCR and fluorescent microscopy.
Figure 1 CLA primes monocytes to an anti-inflammatory MΦ2 macrophage phenotype. RT-PCR analysis of (a) CD14 and CD68 and (b) CD163
and MR mRNA expression in or M-CSF stimulated (100 ng/ml) differentiating HPBMCs following treatment with c-9,t-11-CLA, t-10,c-12-CLA, CLA blend
(80:20 c-9,t-11:t-10,c-12), OA, LA or TROG. In unstimulated conditions, both CLA isomers and their blend decrease CD14 expression and increase
expression of both CD163 and MR, without affecting CD68 expression. Following M-CSF stimulation, c-9,t-11-CLA and CLA blend decrease the mature
macrophage marker CD68 and increase expression of both CD163 and MR (MΦ2 markers). Data are mean +/− SEM of three independent experiments.
Data is expressed as fold change in gene expression relative to DMSO control, where *p < 0.05; ** p < 0.01 and ***p < 0.001 vs DMSO.
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isomers and their 80:20 blend significantly decreased
CD14 mRNA expression (c-9,t-11-CLA by 2 fold, p <
0.05; t-10,c-12-CLA by 1.3 fold, p < 0.05 and 80:20 CLA
blend by 1.4 fold, p < 0.05) via a PPARγ dependent
mechanism, where the PPARγ agonist TROG, also de-
creased CD14 expression (by 3.3 fold, p < 0.01). Al-
though the lipid control OA had no effect, the parent
compound, LA, also decreased CD14 expression, sug-
gesting a general class effect of linoleic acids on un-
stimulated monocytes in early differentiation. The effect
of CLA in repressing CD14 expression in early differen-
tiation, was not maintained upon M-CSF treatment. This
is expected, as CD14 is a monocyte marker which is not
highly expressed in mature differentiated macrophages.
Interestingly, the PPARγ agonist maintained a decrease
in CD14 expression (by 1.3 fold, p < 0.01) suggesting that
activation of PPARγ may inhibit the process of monocyte
to macrophage differentiation even in the presence of
M-CSF. Although the pan-macrophage marker CD68
was not regulated by any lipid treament in unstimulated
macrophages, following stimulation with M-CSF, both c-
9,t-11-CLA and CLA blend decreased CD68 expression
compared to DMSO control (by 1.3 fold, p < 0.01 and by
1.4 fold, p < 0.01, respectively) via a PPARγ dependent
mechanism, where TROG also decreased CD68 expres-
sion (by 1.8 fold, p < 0.001). Conversely, t-10,c-12-CLA,OA and LA had no effect on CD68 expression (Figure 1a).
This suggests a specificity of the atheroprotective CLA
isomer (c-9,t-11) and the CLA blend in alteration of
macrophage phenotype, following monocyte differenti-
ation. This is in keeping with previous studies which show
that the c-9,t-11 isomer, but not the t-10,c-12 isomer, is
atheroprotective [34-36].
In these experiments, CLA was added after four days of
culture, providing a model to investigate how CLA primes
monocytes during their differentiation to macrophages.
Therefore, this data suggests that treatment with the
atheroprotective CLA blend and the c-9,t-11 isomer may
prime monocytes towards an MΦ2 macrophage pheno-
type. This was confirmed by analysis of the expression of
the MΦ2-type marker, CD163 receptor, which also indir-
ectly contributes to an anti-inflammatory response [37]. In
both the presence and absence of M-CSF, c-9,t-11-CLA
and CLA blend increased CD163 expression (in unstimu-
lated cells by 1.5 fold, p < 0.01 and by 1.2 fold, p < 0.01, re-
spectively; in M-CSF stimulated cells by 1.3 fold, p < 0.05
for both treatments). Interestingly, this effect was inde-
pendent of PPARγ, as TROG decreased CD163 expression
in both the absence and presence of M-CSF. Under both
conditions, t-10,c-12-CLA, OA and LA had no effect on
target gene expression, again confirming specificity for the
atheroprotective isomers in altering macrophage pheno-
type (Figure 1b).
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rophages [38,39] and is a well characterised MΦ2-type
phenotype marker [8,14,40].
mRNA analysis of MR showed that, in both unstimu-
lated and M-CSF-stimulated conditions, c-9,t-11-CLA and
CLA blend increased MR expression. In the absence of
M-CSF, MR expression was increased by c-9,t-11-CLA
and CLA blend (by 1.6 fold, p < 0.01 and 1.9 fold, p <
0.001, respectively) and this effect was maintained upon
stimulation with M-CSF (c-9,t-11-CLA by 1.6 fold, p <
0.05 and the CLA blend by 1.3 fold, p < 0.05) (Figure 1b).
In contrast, although t-10,c-12 increased MR expression
by 1.8 fold (p < 0.01), in unstimulated conditions, this ef-
fect was not observed upon stimulation with M-CSF. Fur-
thermore, neither OA nor LA had any effect on MR
expression.
To validate the hypothesis that transcriptional changes
may influence protein expression, we also performed im-
munocytochemistry of the pan-macrophage marker
CD68 and of the MΦ2-type receptor MR, in HPBMCs ei-
ther unstimulated (Figure 2a) or under M-CSF-stimulated
conditions (Figure 2b). Immunofluorescence microscopy
and subsequent spectrophotometric quantification of the
fluorescent signals (Figure 2c) showed that, in unstimu-
lated conditions, CLA had no effect on CD68 expression
but upon M-CSF stimulation, both the c-9,t-11 isomer
and CLA blend decreased CD68 (by 10 ± 1%, p < 0.01 and
18 ± 1%, p < 0.001, respectively). Importantly, in mature
macrophages following M-CSF stimulation, c-9,t-11-CLA
and CLA blend increased MR expression (by 57 ± 7% p <
0.01 and 55 ± 9%, p < 0.01, respectively). Finally, t-10,c-12-
CLA, OA and linoleic acid had no effect on CD68 or MR
expression under either condition. This confirms that
the atheroprotective CLA isomer and blend primes
monocytes to an MΦ2 phenotype during differentiation,
thus altering the macrophage phenotype. Negative con-
trols for immunofluorescence experiments are shown in
“Additional Information” (Additional file 3).
CLA reduces foam cell formation via a PPARγ/LXRα-
dependent regulation of cholesterol metabolism
LXRα, LXRβ and PPARγ are ligand-activated nuclear re-
ceptors controlling cholesterol distribution and efflux,
the inflammatory response and, in the case of PPARγ,
macrophage polarization state. As described above, the ef-
fect of CLA on priming monocytes towards an MΦ2
phenotype is mediated in part via a PPARγ dependent
mechanism. To understand the functional consequences of
CLA in priming monocytes to alternatively activated mac-
rophages, in the next set of experiments, we investigated
the effect of CLA on foam cell formation in HPBMC-
derived macrophages. Freshly isolated HPBMCs were
differentiated towards a macrophage phenotype using 100
ng/ml M-CSF. After 8 days of culture cells were treated for48 hrs with CLA or controls. To investigate the putative
role of PPARγ and LXRα receptor in mediating the effect
of CLA, the synthetic PPARγ agonist, TROG (10 μM) and
LXRα agonist, T0901317 (also known as T1317) (1 μM)
were used as controls. Following treatment, mature macro-
phages were loaded with 50 μg/ml Dil-ox-LDL for 4 hrs to
induce foam cell formation. Similar to what we previously
observed in RAW macrophage cells [31], immunofluores-
cence microscopy and its relative quantification clearly
showed that both c-9,t-11-CLA and t-10,c-12-CLA isomers,
as well as their 80:20 blend, decreased ox-LDL uptake (by
23 ± 3%, p < 0.01; 15 ± 4%, p < 0.05 and 16 ± 4%, p < 0.05,
respectively), whereas LA control had no effect. Interest-
ingly, both the PPARγ and LXRα agonists also inhibited
foam cell formation (by 38 ± 2%,p < 0.001 and 36 ± 11%, p
< 0.05, respectively), suggesting a dual PPARγ/LXRα-
dependent mechanism, through which CLA inhibits foam
cell formation (Additional file 4).
To elucidate the mechanism through which CLA, by
inducing an MΦ2 phenotype, inhibits foam cell forma-
tion, we next examined expression of the scavenger re-
ceptors SR-A1 and CD36 in human macrophage-derived
foam cells (Figure 3a). Although CLA had no effect on
SR-A1 expression, both c-9,t-11-CLA and CLA blend in-
creased CD36 expression in the presence of ox-LDL (by
1.3 fold, p < 0.01 for both), whereas, neither t-10,c-12-
CLA isomer nor either of the two fatty acid controls
modulated CD36 expression.
Furthermore, both CLA isomers and their 80:20 blend
increased ABCA-1 mRNA expression (by 1.4 fold, p <
0.01; 1.2 fold, p < 0.05 and 1.6 fold, p < 0.05, respect-
ively). However, the fatty acid controls also increased
ABCA-1 expression, suggesting that the induction of ef-
flux proteins is a generalised fatty acid effect, whereas,
the regulation of CD36 is unique to the atheroprotective
CLA isomers and blend. To identify the mechanisms in-
volved in increased CD36 and ABCA-1 levels, expression
of the nuclear receptors, which regulate cholesterol
transport and macrophage polarization, were investi-
gated in both the presence and absence of CLA. In ox-
LDL treated macrophages, c-9,t-11-CLA and the 80:20
CLA blend increased PPARγ expression (by 1.5 fold, p <
0.05 and by 1.3 fold, p < 0.05 respectively). As expected,
the receptor agonist TROG also increased its expression
by 1.6 fold (p < 0.05). Furthermore, CLA isomers and
their blend, as well as the PPARγ agonist, induced a
marked increase in the expression of the nuclear recep-
tor LXRα (c-9,t-11-CLA and CLA blend by 1.9 fold, p <
0.05; t-10,c-12-CLA by 1.6 fold, p < 0.05 and TROG by
2.3 fold, p < 0.05). This is a potent and specific effect of
CLA, as neither fatty acid control affected expression.
As positive controls, the effects of two LXRα agonists,
T1317 and 25-OH, were verified on the nuclear receptor
LXRα and on its target gene ABCA-1 in HBPMCs-
Figure 2 CLA inhibits CD68 and increases MR expression in HPBMC-derived macrophages. (a) Freshly isolated HBPMCs were cultured for
four days in the presence or absence of M-CSF and treated with c-9,t-11-CLA, t-10,c-12-CLA, CLA blend (80:20 c-9,t-11:t-10,c-12), OA, LA or TROG
for a further 48 hrs. At day 6, macrophage were fixed and stained. Immunofluorescence analysis of unstimulated macrophage shows that both
CLA isomers and their blend increase MR expression but do not affect CD68 expression. (b) Differentiation of HBPMCs in the presence of 100 ng/ml
M-CSF showed that c-9,t-11-CLA and CLA blend inhibits CD68 expression and increases MR expression. Epifluorescent microscope images
(63× magnification) are representative of three independent experiments. Blue indicates DAPI (nuclei), green indicates CD68 (macrophage
marker), cyan indicates MR and red indicates phalloidin (cytoplasmic) staining. (c) Spectrophotometry quantification of CD68 and MR
fluorescent signal confirms the regulation of CD68 and MR by c-9,t-11-CLA and the atheroprotective blend. Statistical analysis of three
independent experiments is expressed mean % as fluorescence ± SEM vs vehicle where *p < 0.05; **p < 0.01 and ***p < 0.001.
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increased LXRα expression (Additional file 5). Taken to-
gether, this data strongly suggests that the atheroprotec-
tive c-9,t-11-CLA and CLA blend-mediated regulation of
CD36 and ABCA-1 expression is via PPARγ and LXRα
dependent mechanisms.
To confirm our hypothesis, we extended our studies to
examine the effect of the atheroprotective CLA isomer
and the blend on the expression of PPARγ and LXRα
target genes CD36 and ABCA-1, in the presence and
absence of PPARγ or LXRα antagonists, in a distinct
model of macrophage differentiation, namely PMA-
induced THP-1 macrophage formation (Figure 3b and c).
As confirmation of a CLA PPARγ − dependent mechan-
ism, pre-incubation with the PPARγ antagonist, GW9662,
attenuated the effect of both c-9,t-11-CLA and CLA blend
(by 0.3 fold, p < 0.05, for both) on CD36 expression, simi-
lar to that observed when the PPARγ agonist, TROG andthe antagonist GW9662 were combined (by 0.4 fold, p <
0.05). This provides convincing evidence that regulation of
CD36 expression by c-9,t-11 and CLA blend is PPARγ
dependent. Importantly, the CLA-induced increased ex-
pression of ABCA-1 was completely abolished by pre-
incubation with the LXRα antagonist GSK2033 (by 1 fold,
p < 0.01, for both), similar to that observed when the
LXRα agonist, T1317, and the antagonist GSK2033 were
combined (by 1 fold, p < 0.01). This provides convincing
data that CLA mediated regulation of ABCA-1 expression
is LXRα dependent. These experiment confirm the specifi-
city of CLA in modulation of macrophage function via
both PPARγ and LXR-dependent mechanisms.
CLA reduces intracellular cholesterol in foam cells
As CLA alters the macrophage to an MΦ2 MR+ve pheno-
type, we hypothesized that a potential functional effect of
CLA on MΦ2 macrophages in response to ox-LDL and
Figure 3 CLA increased CD36 and ABCA-1 expression via a PPARγ/LXRα mechanism. (a) RT-PCR analysis of SRA-1, CD36, ABCA-1, PPARγ and
LXRα in HPBMC-derived macrophages pre-treated with c-9,t-11; t-10,c-12; CLA blend; OA; LA; TROG or T1317 and stimulated with ox-LDL for 4
hours to induce foam cell formation. CLA blend and c-9,t-11 increase CD36 and ABCA-1. Although t-10,c-12 has no effect on SR expression, it
incresases ABCA-1, which is a generalized effect of linoleic acids. The same effect was observed with the parent compound LA. RT-PCR analysis of
(b) CD36 and (c) ABCA-1 mRNA expression in PMA-induced macrophages treated with c-9,t-11, CLA blend and TROG alone or in combination
with the PPARγ and LXRα antagonists (GW9662 and GSK2033, respectively). Pre-treatment with the antagonists attenuates or abolished the
CLA-induced upregulation of both CD36 and ABCA-1, respectively. Statistical analysis of three independent experiments is expressed as fold
change expression relative to DMSO control where *p < 0.05; **p < 0.01 and ***p < 0.001 or relative to the combination of the antagonist and the
antagonist vs the agonist alone, where #p < 0.05 or ##p < 0.01.
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intracellular cholesterol by promoting efficient cholesterol
metabolism.
To address our hypothesis, we investigated the effect
of CLA on intracellular cholesterol trafficking. To this
end, HBPMCs-derived MCSF-induced macrophages
were analysed for intracellular cholesterol content, fol-
lowing CLA treatment and subsequent ox-LDL loading,
using the Amplex red cholesterol assay. Subsequently,
we measured the fluorescent signals generated by the ac-
tivity of both cholesterol oxidase and esterase, calculat-
ing the content of both free cholesterol (FC) and total
cholesterol (TC). c-9,t-11-CLA significantly decreased
the levels of TC by 29 ± 9% (p < 0.05) and of FC by 36 ±
5% (p < 0.01) and CLA blend reduced TC by 36 ± 11%
(p < 0.05) and FC by 44 ± 7% (p < 0.01). Importantly, nei-
ther the t-10,c-12-CLA isomer nor OA had any signifi-
cant effect on TC although they both reduced FC. ThePPARγ agonist TROG also reduced TC by 28 ± 7% (p <
0.05) and FC by 39 ± 12% (p < 0.05) and the LXRα agon-
ist T1317 reduced TC by 65 ± 12% (p < 0.01) and FC by
89 ± 2% (p < 0.001). This data confirms that the overall
effect of the c-9,t-11-CLA isomer and the CLA blend on
cholesterol trafficking is regulated by a dual mechanism:
a PPARγ-dependent pathway, controlling cholesterol in-
flux (as previously confirmed by the regulation of CD36)
and an LXRα-dependent mechanism, directly influen-
cing the cholesterol efflux (through upregulation of the
efflux protein ABCA-1, as previously shown) (Figure 4).CLA inhibits production of pro-inflammatory cytokines in
human macrophages and foam cells
It is now widely accepted that the cytokine microenvir-
onment plays a fundamental role in the priming and
switching of MΦ1/MΦ2 macrophage subtypes [41].
Figure 4 CLA reduces intracellular cholesterol content of human macrophage derived foam cells. HBPMCs-derived M-CSF stimulated
macrophages, following treatment with c-9,t-11-CLA, t-10,c-12-CLA, CLA blend (80:20 c-9,t-11:t-10,c-12), OA, LA or TROG were ox-LDL loaded for 4
hours and cholesterol content measured by enzymatic assay. CLA blend and c-9,t-11-CLA significantly decrease the levels of both total cholesterol
(TC) and free cholesterol (FC), whilst, t-10,c-12-CLA and OA decrease the FC fraction. The effect of CLA on cholesterol trafficking is regulated by a
dual mechanism involving PPARγ/LXRα-dependent. Data are expressed as % of TC or FC content over vehicle control, where *p < 0.05, **p < 0.01
and are the mean of three independent experiments.
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inflammatory cytokine generation was reduced in ma-
ture macrophages by CLA, in a similar manner to that
of the PPARγ agonist (TROG) (Figure 5a). c-9,t-11-
CLA significantly inhibited IL-6 and IL-1β generation
(by 26 ± 10%,p < 0.01 and by 23 ± 2%, p < 0.05, respect-
ively) and the CLA blend inhibited IL-1β, INF-γ and
IL-12p70 (by 23 ± 5%,p < 0.05; by 20 ± 3%, p < 0.01 and
by 36 ± 12%, p < 0.05, respectively). Interestingly, t-10,
c-12-CLA also reduced IL-1β, INF-γ and IL-12p70 (by
30 ± 3%,p < 0.01; by 19 ± 8%, p < 0.05 and by 26 ± 11%,
p < 0.05, respectively). Coincident with its role in
macrophage polarisation, the PPARγ agonist inhibited
all pro-inflammatory cytokines analysed. Importantly,
c-9,t-11-CLA also increased anti-inflammatory cyto-
kine IL-10 generation in macrophages (by 2.1 fold, p <
0.05), suggesting a specificity of this isomer to pro-
foundly alter the cytokine profile of the marophage
cells. Furthermore, we showed that the altered cyto-
kine profile was maintained following stimulation of
foam cell formation where pro-inflammatory cytokines
generation was reduced by CLA, in a similar manner
to that of the PPARγ agonist (TROG) (Figure 5b). In
particular, c-9,t-11-CLA significantly inibited IL-6 and
INF-γ generation (by 34 ± 15%, p < 0.05 and by 37 ±
12%, p < 0.05, respectively) and the CLA blend inibited
IL-6, TNF-α and INF-γ (by 65 ± 4%,p < 0.001; by 42 ±
17%, p < 0.05; by 49 ± 6%, p < 0.01, respectively). t-10,c-
12-CLA also reduced IL-6, TNF-α and IL-12p70 (by
51 ± 7%,p < 0.01; by 40 ± 16%, p < 0.05 and by 38 ± 17%,
p < 0.05, respectively) and TROG reduced generation
of IL-6, TNF-α, INF-γ and IL12p70.
Again, c-9,t-11-CLA increased IL-10 generation in
foam cells by 1.8 fold (p < 0.05). Finally, fatty acid con-
trol LA had no effect on any of the cytokines analyzed.In summary, in both macrophage and foam cell, gener-
ation of pro-inflammatory cytokines was decreased by
CLA in a similar manner to that of the PPARγ agonist
(TROG) and c-9,t-11 isomer increased the generation of
anti-inflammatory IL-10.
Discussion
Over the last decade, in parallel with the discovery of
several anti-atherogenic properties of CLA [27,28], sev-
eral studies have focused on identifying the cellular
mechanism through which CLA mediates its effect with
several lines of evidence, including our previous studies,
suggesting that it is via the monocyte/macrophage cell
[4,17,25,26,29-31]. To date, the effect of CLA on the
modulation of macrophage/foam cell phenotype and
function have primarily been conducted in cell lines, in
particular the murine RAW-264.7 [35,36] and the hu-
man THP-1 cells [29], as well as in murine [27] and
rabbit models of atherosclerosis [21,28,42]. Not surpris-
ingly, the use of in vivo models, ex vivo cell culture sys-
tems and/or in vitro immortalised cell lines, as well as
different isomeric blends of CLA, have resulted in con-
flicting data in relation to the effect of CLA on macro-
phage function.
In this study, we used a translationally relevant cell
model, namely human peripheral blood monocytes, to
elucidate the effect of CLA on macrophage plasticity,
foam cell formation, intracellular cholesterol metabolism
and cytokine generation. Importantly, we examined the
effect of the 80:20 blend, previously shown by us to in-
duce regression and inhibit foam cell formation [25,31],
as well as the atheroprotective isomer c-9,t-11 which in-
hibits monocyte adhesion/migration [4,29]. We also ex-
amined the t-10,c-12 isomer as a control, which has
previously been shown to have no effect and, in some
Figure 5 CLA inhibits production of pro-inflammatory citokine secretion in human macrophages and foam cells. Measurement of
cytokine released was quantified in HPBMC-derived (a) macrophages and (b) foam cells following treatment with c-9,t-11; t-10,c-12; CLA blend;
OA; LA or TROG using a multiplex ELISA. Both individual CLA isomers and the CLA bend reduced pro-inflammatory cytokine generation via a
PPARγ dependent mechanisms. Uniquely, c-9,t-11-CLA increased macrophage and foam cell generation of IL10, via a PPARγ independent
mechanism. Data are expressed as % cytokine release over vehicle control and are the mean of three independent experiments where *p < 0.05,
**p < 0.01, ***p < 0.001.
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CLA is a known ligand for the nuclear receptor PPARγ
[44,45] and is thus a potential pathway through which
CLA mediated its atheroprotective effects [33], we have
recently shown that the effect of CLA on monocyte
function is mediated via both PPARγ dependent and in-
dependent mechanisms [4] and, in this study, we identify
that CLA mediates its effects on the macrophage/foam
cell via an additional LXRα dependent mechanism.
Macrophage differentiation is diversely regulated by
several growth factors [46]. A major aim of this study
was to examine if CLA primes human monocytes to
adopt an MΦ2 phenotype. To address this, we used M-
CSF, a known inducer of macrophage polarization [47]
and the effect of CLA isomers and the atheroprotective
blend on the mRNA expression of macrophage markers
was analysed, in the presence or absence of M-CSF
stimulation. We show that, during early stages of
monocyte-macrophage differentiation, modeled in vitro
by the absence of M-CSF, both CLA isomers and the
80:20 blend decreases CD14, a receptor specific to the
“monocytic phase” of the cell [48], whilst, as differenti-
ation progresses, the atheroprotective CLA isomer de-
crease CD68 expression, a receptor which characterizes
later stages of macrophage cell development [40]. Of im-
portance is the observation that CLA also upregulatesthe specific MΦ2-type markers CD163 and MR [14],
priming a switch towards an anti-inflammatory macro-
phage phenotype. Our data suggest a potential PPARγ-
dependent mechanism of CLA in the regulation of the
aforementioned receptors. Indeed, this is supported by
Bouhlel et al., who showed that PPARγ activation primes
human monocytes into alternative macrophage, charac-
terized by high levels of MR, positively related to highly
expressed PPARγ [14].
In the absence of differentiating stimulus, in early
monocyte-macrophage differentiation, both c-9,t-11-CLA
and the atheroprotective CLA blend promoted a
CD68high/MRhigh phenotype, whilst, when M-CSF-
triggered, switched to a CD68med/MRhigh and a CD68low/
MRhigh phenotype, thereby also regulating CD68 protein
expression. Moreover, stimulation with M-CSF, amplifies
the effect of c-9,t-11-CLA on the mannose receptor, which
although expressed in resting conditions, albeit at very low
levels, is significantly increased following treatment. Im-
portantly, this data identifies a putative atheroprotective
role for CLA, specifically c-9,t-11 isomer, in priming
monocytes towards MΦ2 macrophage phenotype.
To fully understand the functional consequences of al-
tered macrophage phenotype on foam cell formation,
HPBMC-derived macrophages were pre-treated with CLA
isomers prior to the addition of the pro-atherogenic ox-
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formation, and t-10,c-12-CLA isomer induced a similar, al-
though less pronounced effect. Interestingly, both agonists
of PPARγ and LXRα inhibited foam cell formation, sug-
gesting a possible dual PPARγ/LXRα-dependent mechan-
ism, through which CLA prevents foam cell formation.
This is in keeping with our recent study on RAW macro-
phage cells, which shows that CLA mediates its effect on
foam cell formation via regulation of PGC-1α, the tran-
scriptional activator of both PPARγ, LXR and other nu-
clear receptors [31].
The canonical route for ox-LDL to enter the cell is via
scavenger receptor-mediated uptake and inhibition of
CD36 and SRA-1 scavenger receptor expression has
been shown to limit foam cell formation [49]. However,
a second potential mechanism for the inhibition of foam
cell formation is via the RCT system which removes
cholesterol to HDL for metabolism in the liver. Primar-
ily, the ABC transporters, including ABCA-1, regulates
RCT. Previous studies have shown that LXRα regulates
cholesterol trafficking via modulation of ABC efflux pro-
teins [8]. Thus, to better understand the mechanism
through which CLA inhibits foam cell formation, both up-
take and efflux of ox-LDL was examined, initially by ana-
lysing the expression of SR-A1, CD36 [49,50] and ABCA-1
[9,51] following ox-LDL loading of mature HPBMC-
derived macrophage. Furthermore, using the PMA-
induced THP-1 macrophage cell line model, regulation of
the aforementioned two nuclear receptors’ target genes
CD36 and ABCA-1 expression was also verified in the
presence of CLA isomers alone or in combination with
PPARγ and LXRα antagonists, which, respectively, attenu-
ates or abolished the CLA-induced upregulation of those
genes. This data confirms that ox-LDL influx and efflux is
controlled by a dual PPARγ/LXRα-dependent mechanism.
Our data shows that CLA inhibits foam cell formation,
in the presence of an exogenous source of oxidized lipo-
proteins, by increasing expression of the PPARγ target
CD36, thus promoting the uptake of the relatively abun-
dant presence of circulating lipids, mimicked in vitro by
loading cells using ox-LDL, which is known to activate
PPARγ [52]. In parallel with the increased lipid uptake,
an increased efflux of those lipids is induced by CLA via
upregulation of the LXRα target ABCA-1. This is in
keeping with previous studies where it has been estab-
lished that increased PPARγ activity results in an in-
crease in CD36 and a decrease in SRA-1 expression [52]
and that a crosstalk between the two nuclear receptors,
PPARγ and LXRα, induces a CD36-mediated positive
regulation of ABCA-1 [53-55]. Interestingly, during early
stages of macrophage differentiation, we show that the
PPARγ agonist significantly reduced ABCA-1 (data not
shown), whilst, in foam cells, ABCA-1 expression is res-
cued to the control level. This is likely due to the factthat ox-LDL activates the PPARγ nuclear receptor, there-
fore, its agonist, mediates the restoration to a basal
ABCA-1 expression as previously documented [56,57].
Under normal homeostatic conditions, lipid that is
taken into the macrophage can be efficiently metabolised
and trafficked out of the cell via the RCT system, result-
ing in a balance between lipid uptake and efflux. In an
atherogenic environment, however, where there are high
concentrations of ox-LDL, there is a continuous influx
of lipid and the increased intracellular concentration of
free cholesterol overwhelms the RCT system. Excess
cholesterol becomes esterified into cholesterol esters,
which form lipid droplets, the distinctive features of
foam cells. Therefore, to further confirm the proposed
mechanism through which CLA inhibits foam cell for-
mation, intracellular cholesterol content was analysed. c-
9,t-11-CLA and CLA blend, significantly decreased the
levels of both free and esterified cholesterol, confirming
their specificity in atheroprotection, and reduced ox-
LDL uptake, preventing intracellular accumulation of es-
terified cholesterol, whilst simultaneously, inducing free
cholesterol efflux. The net effect of CLA, which primes
the macrophages towards an MΦ2 phenotype prior to
foam cell challenge, is altering cholesterol trafficking and
lipid storage. Based on the data presented, it is feasible
to suggest that CLA induces the macrophage to adopt
an an anti-inflammatory phenotype which limits foam
cell formation. To further address the inflammatory pro-
file of CLA primed macrophages, the effect of CLA on
cytokine generation was investigated.
The role of cytokine microenvironment on cholesterol
metabolism has been extensively studied, playing a fun-
damental role in the priming of MΦ1/MΦ2 macrophage
subtypes [41]. Therefore, macrophage generation of pro-
inflammatory cytokines, namely, IL-1β, IL-6, IL-12p70,
INF-γ and TNF-α were quantified, following CLA treat-
ment of HPBMC-derived macrophages. Overall, in both
macrophage and foam cells, the generation of most of
the pro-inflammatory cytokines was prevented by CLA
via a PPARγ-dependent mechanism. In general, the CLA
conferred a “resolving” macrophage phenotype [11].
Moreover, it has been shown that IL-10 prevents pro-
inflammatory cytokine production by activated macro-
phages, as part of its “deactivation” programme [58].
Supporting this is the observation that IL-10 production
has been shown to be predominantly found in CD14low/
CD16high or “anti-inflammatory” monocytes [59]. Indeed
our recent work demonstrated that IL-10 signalling path-
way was modified during CLA-induced regression in mur-
ine model [17]. In keeping with this, we show that the
atheroprotective isomer c-9,t-11-CLA increases macro-
phage and foam cell IL-10 production. However, this is
not a PPARγ-mediated effect, as TROG actually decreases
IL-10 generation in HBPMC-derived macrophage and has
Figure 6 Potential atheroprotective mechanism of CLA on the macrophage/foam cell axis. (a) Th-1 cytokine environment primes M-CSF-triggered
monocyte differentiation towards an MΦ1 macrophage pro-inflammatory phenotype. (b) Th-2 cytokine environment primes M-CSF-triggered monocyte
differentiation towards an MΦ2 macrophage anti-inflammatory phenotype. (c) CLA action primes M-CSF-triggered monocyte differentiation towards an
MΦ2-type macrophage. (d) In the presence of high levels of lipids in the extracellular matrix, CLA induces a dual mechanism PPARγ/LXRα-mediated (i-ii),
by increasing CD36 levels (iii), allowing lipids to enter the cell (iv), and secondly, promoting cholesterol efflux, by increasing ABCA-1 mRNA expression (v),
thus preventing lipid engulfment of the cell (vi), and the consequent foam cell formation. Moreover, CLA inhibits the secretion of pro-inflammatory
cytokines (vii).
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this anti-inflammatory effect is due to an LXRα activation,
as it has been shown that the LXRα agonist, T1317, does
not increase levels of IL-10 in CD4-positive T cells [60].
Further studies are needed to investigate the exact mech-
anism of action of the CLA atheroprotective effect on the
anti-inflammatory cytokine generation, which will likely
identify additional PPARγ/LXRα-independent pathways.
Among the pro-inflammatory cytokine panel ana-
lysed, INF-γ was the only one which was decreased in
both macrophage and foam cells by the CLA blend,
strongly suggesting a PPARγ-dependent mechanism
regulating the inhibition of pro-inflammatory media-
tors. This hypothesis is supported by a study where the
PPARγ antagonist GW9662 reversed the decreasedexpression of pro-inflammatory cytokines TNFα, IL-1β
and IL-6 and increased levels of the immunosuppressive
cytokine TGF-β in M2-polarized THP-1 macrophages
[61]. It has been extensively shown that INF-γ increases
the expression of the scavenger receptor SRA-1, in both
THP-1- and HBPMC-derived macrophages [62], and
that DNA binding activity is most likely responsible for
the IFN-γ-dependent expression of SRA-1. In addition,
INF-γ decreases ABCA-1 expression in murine peritoneal
macrophages [63], decreasing cholesterol efflux, through
pathways that include the upregulation of ACAT and the
downregulation of efflux proteins. Based on these findings,
IFN-γ can shift the equilibrium between macrophages and
foam cells and, thus, impact the progression of an athero-
sclerotic lesion [64]. Moreover, it has been shown that
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mRNA expression. In human lymphocytes the LXRα
agonist, T1317 decreased INF-γ, TNF-α and IL-2 levels
[60]. This is in keeping with our data, which shows that
CLA mediates its effect via both a PPARγ and LXRα
dependent mechanisms and decreases macrophage and
foam cell generation of IFN-γ.
Conclusions
In summary, the data provides a novel mechanism for
CLA in atherosclerosis Figure 6. The atheroprotective c-
9,t-11 isomer and the CLA blend negatively regulate ex-
pression of pro-inflammatory mediators via a PPARγ and
LXRα dependent mechanism. As a consequence, differenti-
ation process is shifted towards an anti-inflammatory
MΦ2 phenotype, characterised by increased CD36 and
ABCA-1 expression, thus preventing macrophage lipid en-
gulfment and promoting cholesterol efflux towards exogen-
ous acceptors.
In conclusion CLA, by altering macrophage function,
changes the relative distribution of macrophagic subsets,
acquiring an anti-inflammatory phenotype which, ultim-
ately, may impact on the lesion microenvironment, thus
contributing to the mechanism through which CLA in-
duces regression of pre-established atherosclerosis.
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